TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31485980

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30380530

Group type: COMPARATOR
Intervention: Oral steroid + intratympanic steroid injection (ITSI) (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral steroid + ITSI + Hyperbaric Oxygen Therapy (HBOT) (Study group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral steroid + ITSI + HBOT (Study group)
Number of subjects: 60
Study: 26104243

Group type: EXPERIMENTAL
Intervention: Medium adherence to Mediterranean diet
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet
Number of subjects: 3042

Group type: COMPARATOR
Intervention: Low adherence to Mediterranean diet
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Wholegrain cereals, fruits, and legumes
Number of subjects: 3042
Study: 24555904

Group type: EXPERIMENTAL
Intervention: Lipotoxin (80 mg liposomes and 200 U BoNT‐A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (N/S)
Number of subjects: 24
Study: 21263014

Group type: EXPERIMENTAL
Intervention: Novel formulation of C1 esterase inhibitor concentrate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reference product of C1 esterase inhibitor concentrate
Number of subjects: 13
Study: 20590481

Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Light touch
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 17454518

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose = 4.3 mg/day, SD = 1.2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Quetiapine (mean dose = 300 mg/day, SD = 66.7)
Number of subjects: 22
Study: 15924813

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 545

Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 545
Study: 12495317

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9697878

Group type: EXPERIMENTAL
Intervention: Chemotherapy with Cyclosporin A (CsA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chemotherapy without Cyclosporin A (CsA)
Number of subjects: 46
Study: 8570345

Group type: EXPERIMENTAL
Intervention: Index of Productive Syntax
Number of subjects: 29

Group type: COMPARATOR
Intervention: Developmental Sentence Scoring
Number of subjects: 29
Study: 2515160

Group type: EXPERIMENTAL
Intervention: New liquid formulation of Isocillin syrup
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: New liquid formulation of Isocillin syrup plus ethanol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Commercially available penicillin V syrup containing ethanol as solubilizer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isocillin film tablets
Number of subjects: 14
Study: 365322

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31268872

Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 27899747

Group type: EXPERIMENTAL
Intervention: Ticagrelor (n=1933)
Number of subjects: 3858

Group type: COMPARATOR
Intervention: Aspirin (n=1925)
Number of subjects: 3858

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3858

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3858

Group type: COMPARATOR
Intervention: Non-Asian group
Number of subjects: 3858
Study: 26402868

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) delivered in groups of 8 patients and 2 therapists or 4 patients and 1 therapist
Number of subjects: 204

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 204
Study: 22746285

Group type: EXPERIMENTAL
Intervention: Overall psychopathy
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Impulsive antisociality
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Fearless dominance
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Global psychopathy and impulsive antisociality
Number of subjects: 483
Study: 21933039

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Concurrent training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 19178132

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily on days 1-3 and once daily on day 4
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg once daily on days 1-4
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatments together on days 1-4
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dabigatran etexilate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Dabigatran etexilate (combination treatment)
Number of subjects: 22
Study: 17218919

Group type: EXPERIMENTAL
Intervention: Steamroller technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic technique
Number of subjects: 40
Study: 16032385

Group type: EXPERIMENTAL
Intervention: Increased endothelin plasma levels during supine position and head-up tilt in subjects with vasovagal syncope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40
Study: 11926917

Group type: EXPERIMENTAL
Intervention: Retronasal olfactory function assessment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Retronasal olfactory function in normosmic subjects
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Orthonasal and retronasal identification of odors
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Retronasal testing
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Retronasal performance of anosmic patients
Number of subjects: 230

Group type: COMPARATOR
Intervention: Comparison of anosmia of different origin
Number of subjects: 230
Study: 9526179

Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Imipramine 50-100 mg/day
Number of subjects: 198
Study: 7786835

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (spironolactone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ACE inhibitor only)
Number of subjects: 0
Study: 2710907

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (supervised, 3 times per week for 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Strength training (3 times per week for 12 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 27
Study: 1203224

Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride in rabbits
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride in humans
Number of subjects: 2
Study: 30906960

Group type: EXPERIMENTAL
Intervention: Individuals with multiple sclerosis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dynamic stability tasks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Complex walking scenario
Number of subjects: 46
Study: 28636580

Group type: EXPERIMENTAL
Intervention: Positive emotions
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1346
Study: 25451868

Group type: EXPERIMENTAL
Intervention: cTnI above median
Number of subjects: 14806

Group type: EXPERIMENTAL
Intervention: cTnT above median
Number of subjects: 14806

Group type: EXPERIMENTAL
Intervention: Both cTnI and cTnT above median
Number of subjects: 14806

Group type: EXPERIMENTAL
Intervention: One troponin above median
Number of subjects: 14806
Study: 22960747

Group type: EXPERIMENTAL
Intervention: 50% exercise at ambient temperatures of 20, 24, and 28 °C
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20% exercise at 28 °C
Number of subjects: 7
Study: 21806314

Group type: EXPERIMENTAL
Intervention: Alogliptin 6.25 mg once daily
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg once daily
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alogliptin 50 mg once daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Voglibose 0.2 mg three times daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alogliptin (all dosages)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 480
Study: 19558008

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Epinastine, 20 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fexofenadine, 120 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15566589

Group type: EXPERIMENTAL
Intervention: Postoperative glucose levels
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Postoperative glucose concentration
Number of subjects: 151
Study: 10511064

Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg R,R‐enantiomer
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7735495

Group type: EXPERIMENTAL
Intervention: Pansalt (low-Na/high-K salt alternative)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard NaCl (control group)
Number of subjects: 40
Study: 2285009

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6165336

Group type: EXPERIMENTAL
Intervention: Antibiotics for prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibiotics for prophylaxis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intraoperative Gram's stain procedure
Number of subjects: 100
Study: 30615478

Group type: EXPERIMENTAL
Intervention: Generative retrieval (GR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 40
Study: 27904931

Group type: EXPERIMENTAL
Intervention: LHB tenodesis (LHB‐TD) in 49 patients
Number of subjects: 85

Group type: COMPARATOR
Intervention: LHB tenotomy (LHB‐TT) in 36 patients
Number of subjects: 85
Study: 25017013

Group type: EXPERIMENTAL
Intervention: Face mask treatment started after the completion of the Alt‐RAMEC procedure (Group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Face mask treatment started simultaneously with the Alt‐RAMEC procedure (Group II)
Number of subjects: 36
Study: 24952858

Group type: EXPERIMENTAL
Intervention: EDTA chelation + high-dose vitamins
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: EDTA chelation + placebo vitamins
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Placebo infusion + active vitamins
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo infusion + placebo vitamins
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Double active treatment (EDTA + high-dose vitamins) vs double placebo
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Double active treatment (EDTA + high-dose vitamins) vs double placebo in patients with diabetes
Number of subjects: 1708
Study: 23072086

Group type: EXPERIMENTAL
Intervention: Mild-hypothermia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (mild-hypothermia + acupuncture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Acupuncture)
Number of subjects: 90
Study: 19424699

Group type: EXPERIMENTAL
Intervention: Individually tailored protocols (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fixed injection parameters (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional protocols (Group 3)
Number of subjects: 120
Study: 17329192

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (1200/30 mg/m2, days 1 and 8)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2, days 1 and 8)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 252
Study: 16113429

Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0
Study: 11260417

Group type: EXPERIMENTAL
Intervention: Bicarbonate/Lactate (B/L) solution
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (C) solution
Number of subjects: 106
Study: 9482763

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of zinc as zinc sulfate, 4 mL beverage daily for an average of 6.9 months)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 8015632

Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 125 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation (ASTA H995) 275 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-dopa/bensearazid-s.r. preparation
Number of subjects: 12

Group type: COMPARATOR
Intervention: L-dopa standard preparation
Number of subjects: 12
Study: 30047132

Group type: EXPERIMENTAL
Intervention: Paralaminar approach (group PL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intercostal approach (group IC)
Number of subjects: 42
Study: 27698557

Group type: EXPERIMENTAL
Intervention: Tai chi qigong (TCQ) training, 2 sessions of 60 minutes each week for 2 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tai chi qigong (TCQ) training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 52
Study: 25504466

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (RTP) + Cognitive Stimulation (CS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch (RTP)
Number of subjects: 90
Study: 23630366

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 54
Study: 20627703

Group type: EXPERIMENTAL
Intervention: COMT pain sensitivity haplotype (SNPs rs6269, rs4633, rs4818, rs4680)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: rs165599 SNP
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 159
Study: 20002476

Group type: EXPERIMENTAL
Intervention: Pioglitazone (force titrated to 45 mg/day)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1515
Study: 17218108

Group type: EXPERIMENTAL
Intervention: Aprotinin (1 million IU)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2.5g)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 15051755

Group type: EXPERIMENTAL
Intervention: Standard radiation therapy (60 Gy in 30 fractions over 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shorter course of radiation therapy (40 Gy in 15 fractions over 3 weeks)
Number of subjects: 100
Study: 11280620

Group type: EXPERIMENTAL
Intervention: Aspect A‐1000 measuring BIS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Drager pEEG measuring SEF90%
Number of subjects: 28
Study: 9476566

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study: 7614865

Group type: EXPERIMENTAL
Intervention: CT scan of the hip
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional radiographic assessment
Number of subjects: 30
Study: 3360951

Group type: EXPERIMENTAL
Intervention: Voluntary short-term abstinence from alcohol for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (drank as usual)
Number of subjects: 36
Study: 28980055

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg/kg tranexamic acid (Group T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone and 10 mg/kg tranexamic acid (Group DT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 60
Study: 27080916

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 21 days after SWL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg daily for 21 days after SWL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo daily for 21 days after SWL
Number of subjects: 60
Study: 25914193

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24137674

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 22

Group type: COMPARATOR
Intervention: BIS85
Number of subjects: 22
Study: 20934876

Group type: EXPERIMENTAL
Intervention: Continuous target cues
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: End-point cues
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: End target cues
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous targets
Number of subjects: 40
Study: 19049552

Group type: EXPERIMENTAL
Intervention: Evidence-based patient decision aid (DA)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Standard information (Control Group)
Number of subjects: 297
Study: 16175942

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day + Irbesartan 300 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 12925633

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated external fixation pins
Number of subjects: 17

Group type: COMPARATOR
Intervention: Uncoated external fixation pins
Number of subjects: 17
Study: 10745299

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study: 8634617

Group type: EXPERIMENTAL
Intervention: Nurse led programme using a family centered approach, with follow up according to degree of risk
Number of subjects: 7008
Study: 1508840

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) + Lorazepam (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6685963

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-amphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31746766

Group type: EXPERIMENTAL
Intervention: Interactive mobile phone app (SMART 5-A-DAY)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 94
Study: 29957370

Group type: EXPERIMENTAL
Intervention: Antidepressants (ADs)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 263
Study: 27565921

Group type: EXPERIMENTAL
Intervention: E300 (300 mg erlotinib)
Number of subjects: 313

Group type: COMPARATOR
Intervention: E150 (150 mg erlotinib)
Number of subjects: 313
Study: 24635528

Group type: EXPERIMENTAL
Intervention: Ketamine and magnesium (Gr K + Mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketamine alone (Gr K)
Number of subjects: 50
Study: 21725826

Group type: EXPERIMENTAL
Intervention: Experimental group (ER) received 670 nm gallium‐aluminum‐arsenide light-emitting diode device for 80 s at 50 mW/cm² energy density and power exposure of 4 J/cm².
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo group (PR) received identical device but <5 mW/cm² energy density.
Number of subjects: 80
Study: 19175450

Group type: EXPERIMENTAL
Intervention: Prolonged detection interval of 30/40 seconds for life threatening ventricular tachyarrhythmia (VT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard detection interval of 18/24 seconds for life threatening ventricular tachyarrhythmia (VT)
Number of subjects: 0
Study: 17939076

Group type: EXPERIMENTAL
Intervention: Intramedullary splints (n=35)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Figure of eight dressing (n=33)
Number of subjects: 68
Study: 15482081

Group type: EXPERIMENTAL
Intervention: Phoenix Academy treatment
Number of subjects: 449

Group type: COMPARATOR
Intervention: Alternative probation disposition
Number of subjects: 449
Study: 12575390

Group type: EXPERIMENTAL
Intervention: Qihuang oral liquid (QHOL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 9653824

Group type: EXPERIMENTAL
Intervention: External drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study: 8171952

Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg.kg‐1 intravenously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 3048224

Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 1 mg/h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 2 mg/h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide at 4 mg/h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30905173

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 8 weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait-list control (standard care)
Number of subjects: 87
Study: 27984918

Group type: EXPERIMENTAL
Intervention: Baclofen treatment for AUD
Number of subjects: 792